Xcout Intel
Adcendo competitors & alternatives
The 12 closest competitors and alternatives to Adcendo among biotechnology companies — ranked by similarity to what Adcendo actually does, not by market-cap band.
Subscribe to see Adcendo’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Adcendo
Adcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with supplementary operations in Boston, Massachusetts. The company specializes in the development of innovative antibody-drug conjugates (ADCs) targeting various oncology indications. Its pipeline focuses on delivering best-in-class clinical treatments for patients with high unmet medical needs.
Adcendo at a glance
Adcendo is a biotechnology company headquartered in Denmark. It has raised at least $261M across the 3 funding rounds on record. Its most recent funding round, Series B, raised $75M in April 2026. Xcout tracks 15 named people at Adcendo, including Michael Pehl (Chief Executive Officer).
Adcendo leadership
- Michael PehlChief Executive Officer
- Fang Z. NiChief Financial Officer
- Pernille HemmingsenChief Technology Officer
- Dominik MumbergChief Scientific Officer
- Lone H. OttesenChief Medical Officer
- James WangVP, Head of Business Development
9 more named people on record for Adcendo, with roles, board committees and tenure — see the full roster →
Adcendo funding rounds
At least $261M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $75M | 13 named | |
| Series B | $135M | 13 named | |
| — | $51M | 14 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Adcendo competitors
Ranked by semantic similarity — how close each company is to Adcendo by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Adcytherix is a clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugates (ADCs) for oncology. The company combines clinically validated targets with innovative payloads derived from approved cancer drugs to treat resistant cancers and address unmet medical needs.
Similar biotechnology company
VelosBio Inc. is a clinical-stage biopharmaceutical company based in California, United States, focused on developing novel antibody-drug conjugates to transform cancer treatment for patients.
Biotech
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Similar biotechnology company
Centrose LLC is a biotechnology company that develops a next-generation antibody-drug conjugate platform known as Extracellular Drug Conjugates (EDCs). These precision medicines target the cell surfaceome by binding multiple extracellular proteins simultaneously without cell internalization or drug release, aiming to create safer and more potent treatments for cancer and drug-resistant tumors.
Similar biotechnology company
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Similar biotechnology company
Pheon Therapeutics is a biotechnology research company headquartered in London, England, that specializes in developing next-generation antibody-drug conjugates for hard-to-treat cancers.
Similar biotechnology company
Tubulis is a biotechnology organization headquartered in Munich that generates uniquely matched antibody-drug conjugates with superior biophysical properties.
Similar biotechnology company
Myricx Bio is a UK biotech company headquartered in London. It specializes in the discovery and development of a novel class of selective cytotoxic payloads for Antibody-Drug Conjugates (ADCs).
Similar biotechnology company
Mythic Therapeutics, Inc. is a biotechnology research company headquartered in Waltham, Massachusetts. The company is dedicated to developing a proprietary platform to enhance the effectiveness of antibody-drug conjugates and other antibody-based therapeutics.
Biotech
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
Similar biotechnology company
Allink Biotherapeutics is a clinical-stage biotechnology company founded in 2023 and based in Shanghai, China, focused on developing advanced antibody-drug conjugates (ADCs) and therapeutics.
Life Sciences
Crescendo Biologics Ltd., associated with originator organization Crescendo Bioscience LLC, is a biotechnology company headquartered in Cambridge, UK. The firm develops targeted drug pipelines, particularly focusing on oncology and PSMA-positive castration-resistant prostatic cancer treatments.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Adcendo and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Adcendoand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →